24.07.2018 08:40:32
|
DGAP-News: curasan grants Private Label-Rights for Hyaluronic Acid used in Osteoarthritis Therapy
DGAP-News: curasan AG / Key word(s): Alliance
Kleinostheim, July 24 2018 - curasan AG, Germany, a leading specialist for medical products in the field of orthobiologics has signed a private-label-agreement with Leader Biomedical to market their hyaluronic acid. The company headquartered in Amsterdam will offer curasan' s hyaluronic acid for osteoarthritis therapy under their own brand, Hyalosyn(TM) Gel. This is a second brand name for curasan' s long-term proven and successfully marketed product Curavisc(R) that improves the lubricating and shock absorbing properties of the body's own synovial fluid. "The two-brand-strategy will open additional buyer groups for our product", says Michael Schlenk, CEO of curasan AG. "Even more, we provide our cooperation partner with a very specific competitive edge, since our hyaluronic acid is one of the few products also indicated for spinal use." "Not only patients with osteoarthritis of the large joints benefit from a therapy with curasan' s hyaluronic acid, but also patients with facet and sacroiliac joint arthritis. It also offers an excellent alternative to a treatment with painkillers and its many side effects", explains Gregor Siebert, Head of Marketing and Sales. "Moreover, the market shows an obvious trend towards a more physiological treatment pattern of multiple injections as recommended by us; this means three to five injections given at weekly intervals instead of just one. Many clinicians are realizing that this therapy pattern results in a more enduring improvement for their patients," adds Florian Früh, Head of Product Management. "In addition to that, our medium molecular weight hyaluronic acid is also indicated for the treatment of stress related pain and first signs of movement limitations within active athletes and leisure sportsmen," he continues. curasan AG and Leader Biomedical already introduced Hyalosyn(TM) Gel to Leader Biomedical' s global network of distribution partners and healthcare professionals on occasion of their Global Symposium, held on 14 and 15 June 2018 in the Netherlands.
24.07.2018 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. |
Language: | English |
Company: | curasan AG |
Lindigstraße 4 | |
63801 Kleinostheim | |
Germany | |
Phone: | 06027/40 900 0 |
Fax: | 06027/40 900 29 |
E-mail: | info@curasan.de |
Internet: | www.curasan.de |
ISIN: | DE0005494538 |
WKN: | 549453 |
Listed: | Regulated Market in Frankfurt (General Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange |
End of News | DGAP News Service |
|
707251 24.07.2018
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu curasan AGmehr Nachrichten
Keine Nachrichten verfügbar. |